Current Antipsychotics

Volume 212 of the series Handbook of Experimental Pharmacology pp 267-298


Delivery Systems and Dosing for Antipsychotics

  • Cara R. RabinAffiliated withDepartment of Obstetrics and Gynecology, School of Medicine, Columbia University
  • , Steven J. SiegelAffiliated withTranslational Research Laboratories, Department of Psychiatry, University of Pennsylvania Email author 

* Final gross prices may vary according to local VAT.

Get Access


Schizophrenia is a devastating illness, affecting approximately 1–2 % of the world population. Age of onset is generally between 20 and 30 years of age with a chronic, unremitting course for the duration of the patient’s life. Although schizophrenia is among the most severe and debilitating illnesses known to medicine, its treatment has remained virtually unchanged for over 50 years. This chapter covers several major concepts in experimental drug development and delivery: (1) the concept of “typical” vs. “atypical” classifications for antipsychotic drugs as it relates to dosing; (2) the development of depot formulations for improved medication adherence; and (3) several promising areas for future therapeutic advances related to the methods and duration of drug administration. These areas include sublingual, injectable, and implantable drug delivery strategies that have the potential to effect rapid and dramatic improvements in schizophrenia outcomes.


Atypicality Adherence Depot formulation Chlorpromazine equivalents Dopamine hypothesis of schizophrenia Dosing equivalents of antipsychotics Release mechanisms Implants for long-term delivery Sublingual drug delivery Transdermal delivery systems